{
    "clinical_study": {
        "@rank": "127586", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Erlotinib 150mg daily oral up to 2 years"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Active Comparator", 
                "description": "NP Chemotherapy for 4 cycles"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to compare 2-year Disease Free Survival Rate (DFSR) in post radical operation\n      IIIA Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor\n      (EGFR) 19 or 21 exon mutation treated Erlotinib vs NP chemotherapy as adjuvant therapy."
        }, 
        "brief_title": "Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation", 
        "completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer Stage III", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  IIIA NSCLC patients according to TMN-staging of Lung Staging Standard version 7 2009,\n             confirmed by histopathology or cytology after radical operation, and having EGFR exon\n             19 deletion mutation or exon 21 L858R single base substitution;\n\n          -  Accept study adjuvant therapy within 4 weeks post radical operation;\n\n          -  ECOP PS 0-1; Life expectancy \u226512 weeks;\n\n          -  Hematology: absolute neutrophil count (ANC) \u22651.5\u00d710^9/L; platelet count \u2265100\u00d710^9/L;\n             hemoglobin concentration \u2265 9.0 g/dL (permit to maintain hematologic criteria by blood\n             transfusion);\n\n          -  Liver Function: TBil \u22641.5xULN; ALT and AST \u22642.5xULN;\n\n          -  Renal Function: Cr \u22641.25xULN, and Ccr \u226560ml/min;\n\n          -  Female patients of childbearing potential must have a negative serum or urine\n             pregnancy test within 7 days before study treatment;\n\n          -  Signed inform consent form by patient or his/her legal representative;\n\n          -  Comply with study protocol and procedure, and be able to take oral medication; Aged\n             \u226518 years and \u226675 years;\n\n          -  Eligible patients of reproductive potential (both sexes) must agree to use a reliable\n             method of birth control before enrollment, during the study period and for at least\n             30 days after their last dose of study therapy;\n\n        Exclusion Criteria:\n\n          -  Having treated by Her-Target therapy, i.e. erlotinib, gefitinib, cetuximab,\n             trastuzumab;\n\n          -  Having treated by any systemic anti-tumor therapy of NSCLC, including cytotoxic\n             therapy, target medication treatment (i.e. monoclonal antibody), investigational\n             therapy;\n\n          -  Having local radiotherapy of NSCLC; Upper gastrointestinal physiological disorders,\n             or malabsorption syndrome, or intolerance of oral medication, or active peptic ulcer;\n\n          -  The findings in radical operation are lymph nodes with extracapsular invasion, or\n             fusion, or all of dissection lymph nodes positive by pathology;\n\n          -  Diagnosed other malignant tumor besides NSCLC within 5 years prior the study\n             treatment (except having simple surgical resection with 5-year disease free\n             survival,cured in situ of cervical carcinoma, cured basal cell carcinoma and bladder\n             epithelial tumor);\n\n          -  Confirmed recurrent cancer by Clinical objective evidence (pathology or radiography\n             images) before the study adjuvant therapy;\n\n          -  Known hypersensitivity to platinum, Vinorelbine, EGFR-TKI agents or relevant\n             components in the formulation;\n\n          -  Uncontrolled eye inflammation or infection, or any potential circumstances lead to\n             eye inflammation or infection;\n\n          -  Active interstitial lung disease (ILD) by any clinical evidence; patients with any\n             co-morbidities, or motalic disorders, or any abnormal findings in physical\n             examination or laboratory tests are suspected to have contraindication of study\n             therapy or high risk of study treatment complications;\n\n          -  Any unstable systemic disease, including active infection, uncontrolled hypertension,\n             unstable angina, angina starting in latest 3 months, Congestive heart failure (NYHA \u2265\n             II), myocardial infarction within 6 months prior enrollment, under medication\n             treatment of severe arrhythmia, liver, renal or metabolic disease;\n\n          -  know HIV infection Pregnant or breastfeeding women;\n\n          -  ECOG PS \u22652;\n\n          -  Mixed with small cell lung cancer;\n\n          -  Other conditions investigators evaluate that patient is not eligible to this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "94", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01683175", 
            "org_study_id": "ML28280"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "intervention_name": "Erlotinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "intervention_name": "cis-platinum", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "intervention_name": "Vinorelbine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vinorelbine", 
                "Cisplatin", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Erlotinib", 
            "adjuvant therapy", 
            "radical operation", 
            "IIIA NSCLC", 
            "EGFR mutation"
        ], 
        "lastchanged_date": "June 12, 2013", 
        "location": [
            {
                "contact": {
                    "email": "wangchangli@medmail.com.cn", 
                    "last_name": "Changli Wang", 
                    "phone": "8613821086868"
                }, 
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300060"
                    }, 
                    "name": "Tianjin Medical University Cancer Institute and Hospital"
                }, 
                "investigator": {
                    "last_name": "Changli Wang", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Beijing Chest Hospital\uff0cCapital Medcial University"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "drchu301@yahoo.com.cn", 
                    "last_name": "Xiangyang Chu", 
                    "phone": "8613501222241"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Chinese PLA General Hospital"
                }, 
                "investigator": {
                    "last_name": "Xiangyang Chu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Beijing Cancer Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }, 
                    "name": "The second people's hospital of Sichuan"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "chenchun0209@163.com", 
                    "last_name": "Chun Chen", 
                    "phone": "8613365910325"
                }, 
                "facility": {
                    "address": {
                        "city": "Fuzhou", 
                        "country": "China"
                    }, 
                    "name": "Fujian Medical University Union Hospital"
                }, 
                "investigator": {
                    "last_name": "Chun Chen", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "zhlanj@mail.sysu.edu.cn", 
                    "last_name": "Lanjun Zhang", 
                    "phone": "8613902262187"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "Sun Yat-Sen University Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Lanjun Zhang", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }, 
                    "name": "Zhejiang Cancer Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China"
                    }, 
                    "name": "The third affiliated hospital of Harbin Medical Univer"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "qdshenyi@163.com", 
                    "last_name": "Yi Shen", 
                    "phone": "8613605325078"
                }, 
                "facility": {
                    "address": {
                        "city": "Qingdao", 
                        "country": "China"
                    }, 
                    "name": "The affiliated hospital of medical college Qingdao University"
                }, 
                "investigator": {
                    "last_name": "Yi Shen", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hpchen1@yahoo.com", 
                    "last_name": "Haiquan Chen", 
                    "phone": "8613601973588"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Fudan University Shanghai Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Haiquan Chen", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Zhongshan Hospital Fudan University"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "L24315516@sina.com", 
                    "last_name": "Yongyi Liu", 
                    "phone": "8613898878448"
                }, 
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China"
                    }, 
                    "name": "Liaoning Cancer Hospital & Institute"
                }, 
                "investigator": {
                    "last_name": "Yongyi Liu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shijiazhuang", 
                        "country": "China"
                    }, 
                    "name": "Hebei Provincial Tumor Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "mht7403@163.com", 
                    "last_name": "Haitao Ma", 
                    "phone": "8613375182028"
                }, 
                "facility": {
                    "address": {
                        "city": "Suzhou", 
                        "country": "China"
                    }, 
                    "name": "The first affiliated hospital of Soochow University"
                }, 
                "investigator": {
                    "last_name": "Haitao Ma", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China"
                    }, 
                    "name": "The fourth military medical university\uff0cTangdu Hospital"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Open-labelled, Randomized, Multicenter Phase II Study to Evaluate Efficacy and Safety of Erlotinib vs NP Chemotherapy as Adjuvant Therapy in Post Radical Operation NSCLC Patients With EGFR19 or 21 Exon Mutation", 
        "overall_contact": {
            "email": "wangchangli@medmail.com.cn", 
            "last_name": "Changli Wang", 
            "phone": "8613821086868"
        }, 
        "overall_official": {
            "affiliation": "Tianjin Medical University Cancer Institute and Hospital", 
            "last_name": "Changli Wang", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "China: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "2-year disease free survival rate is defined as the estimation percentage of disease free survival patients with study treatment at 2-year.", 
            "measure": "2-year disease free survival rate (DFSR)", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01683175"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Disease free survival is defined as the time from randomization to disease recurrence or death which comes first.", 
                "measure": "disease free survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Overall survival is defined as the time from randomization to death.", 
                "measure": "overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "The score of Functional Assessment of Cancer Therapy - Lung (FACT-L) subscale and Lung Cancer Symptom Scale (LCSS)", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "frequency of Adverse Event", 
                "measure": "Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Frequency of Serious Adverse Event (SAE)", 
                "measure": "Serious Adverse Event (SAE)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Tianjin Medical University Cancer Institute and Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Roche Pharma AG", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Tianjin Medical University Cancer Institute and Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}